Literature DB >> 24082918

Controversies on individualized prostate cancer care: gaps in current practice.

Steven Joniau1, David Pfister, Alexandre de la Taille, Franco Gaboardi, Alan Thompson, Maria J Ribal.   

Abstract

Prostate cancer (PCa) is a heterogeneous disease with a wide spectrum of aggressiveness. Evidence-based guidelines are invaluable but cannot be expected to be extensive enough to provide detailed guidance on the management of all patients. As such, the use of individualized, risk-adapted approaches to the management of PCa is indispensable. However, wide variation in treatment approaches observed for patients in practice suggests that there is an unmet need to improve the individualized approach towards patient care. A holistic approach that encompasses guidelines and evidence-based medicine could be used to guide individualized care for patients with PCa, from first contact through to final outcomes. As a result of an international expert meeting, this paper proposes this approach and highlights some of the factors that can be considered when aiming to identify patients' profiles; individualize treatment; and improve communication between patients and the healthcare teams.

Entities:  

Keywords:  cancer; guidelines; multidisciplinary communication; prostate; prostatic neoplasm; therapy

Year:  2013        PMID: 24082918      PMCID: PMC3763777          DOI: 10.1177/1756287213490053

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  78 in total

1.  Prostate-specific antigen and prostate cancer prognosis.

Authors:  Timothy R Church
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

2.  A prospective randomized comparison of diagnostic efficacy between transperineal and transrectal 12-core prostate biopsy.

Authors:  A Takenaka; R Hara; T Ishimura; T Fujii; Y Jo; A Nagai; M Fujisawa
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-05-29       Impact factor: 5.554

3.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

4.  Health related quality of life for men treated for localized prostate cancer with long-term followup.

Authors:  George J Huang; Natalia Sadetsky; David F Penson
Journal:  J Urol       Date:  2010-06       Impact factor: 7.450

5.  The prostate cancer pseudo-epidemic.

Authors:  Hans-Olov Adami
Journal:  Acta Oncol       Date:  2010-04       Impact factor: 4.089

6.  Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapy.

Authors:  Andreas Ihrig; Monika Keller; Mechthild Hartmann; Jürgen Debus; Jesco Pfitzenmaier; Boris Hadaschik; Markus Hohenfellner; Wolfgang Herzog; Johannes Huber
Journal:  BJU Int       Date:  2011-03-16       Impact factor: 5.588

7.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Authors:  Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson
Journal:  Lancet Oncol       Date:  2011-08-05       Impact factor: 41.316

8.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

9.  Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance.

Authors:  M Quentin; D Blondin; J Klasen; J Schek; C Buchbender; F R Miese; G Antoch; D Barski; P Albers; C Arsov
Journal:  Urol Int       Date:  2012-06-07       Impact factor: 2.089

10.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

View more
  3 in total

1.  Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study.

Authors:  Indrawarman Soerohardjo; Irianiwati Widodo; Didik Setyo Heriyanto; Andy Zulfiqqar; Sumadi Lukman Anwar
Journal:  Ann Med Surg (Lond)       Date:  2020-11-10

2.  sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients.

Authors:  Igor Tsaur; Kristina Thurn; Eva Juengel; Kilian M Gust; Hendrik Borgmann; Rene Mager; Georg Bartsch; Elsie Oppermann; Hanns Ackermann; Karen Nelson; Axel Haferkamp; Roman A Blaheta
Journal:  J Exp Clin Cancer Res       Date:  2015-05-14

3.  Individualized Integrative Cancer Care in Anthroposophic Medicine: A Qualitative Study of the Concepts and Procedures of Expert Doctors.

Authors:  Gunver S Kienle; Milena Mussler; Dieter Fuchs; Helmut Kiene
Journal:  Integr Cancer Ther       Date:  2016-05-04       Impact factor: 3.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.